Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc Raises Low End Of Prior FY 2012 Revenue Guidance To A Range In Line With Analysts' Estimates-Conference Call


Thursday, 18 Oct 2012 09:00pm EDT 

Cubist Pharmaceuticals Inc announced that it expects fiscal 2012 total revenue to be $915-$930 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $926 million for fiscal 2012. 

Company Quote

65.7
0.74 +1.14%
4:00pm EDT